Gemphire Therapeutics (GEMP) Says First Patients Enrolled in ROYAL-1 Trial for Hypercholesterolemia
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Gemphire Therapeutics Inc. (Nasdaq: GEMP) announced enrollment of its first patients in ROYAL-1, a Phase 2b trial designed to investigate gemcabene in the treatment of patients with hypercholesterolemia not adequately controlled on high-intensity or moderate-intensity stable statin therapy. It is designed to enroll a broad patient population, including patients with heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic cardiovascular disease (ASCVD), who have baseline LDL-C (“bad cholesterol”) values ≥ 100 mg/dL.
“The patient groups we plan to enroll in the ROYAL-1 trial, including patients with HeFH and patients with ASCVD, particularly those with diabetes, represent some of the more prevalent hypercholesterolemia conditions,” said Mina Sooch, President and Chief Executive Officer of Gemphire. “If we are successful in obtaining approval for gemcabene in these populations, we expect to be able to reach a large market of over 10 million patients just in the U.S. that are currently unable to attain their LDL-C goals despite current statin and ezetimibe therapies. Gemcabene, if approved, may offer a competitive and complementary profile as compared with anti-PCSK9 monoclonal antibodies (MAbs), a recently approved class of LDL-C lowering drugs.”
The open-label Phase 2b trial, “A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1)” will enroll up to 104 adult patients at clinical sites in the United States. Patients meeting eligibility requirements are being randomized in a 1:1 ratio to 600mg of gemcabene or placebo. The primary endpoint is the percent change from baseline of LDL-C at 12 weeks. Secondary endpoints include the change from baseline in non-HDL-C, total cholesterol, triglycerides, ApoB, and hsCRP at the 12-week time point.
“We have seen significant interest in the study from principal investigators in the first week of enrollment which reinforces this large unmet patient need despite current available therapies,” shared Dr. Lee Golden, Chief Medical Officer. "Gemcabene is an oral once-daily drug candidate with broad lipid-lowering and anti-inflammation attributes in patients on background stable statin therapy that has been previously studied in a Phase 2 trial and summarized in a recently published paper in the Journal of Clinical Lipidology."
Gemphire currently anticipates the 12-week study to complete enrollment and all patient follow-up visits in the second half of 2017. Additional information on the trial design, including eligibility criteria and site locations, can be found at www.clinicaltrials.gov, using the NCT Identifier NCT02634151.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shire's (SHPG) Phase 3 Investigational Study of VONVENDI Meets Primary Endpoint in Controlling Bleeding in Adults with VWD
- Ignyta (RXDX) to Offer Entrectinib Combo Update in TRK Inhibition in Late-Breaking Presentation at 2016 EORTC-NCI-AACR
- Sears Holdings (SHLD) Director Mnuchin Resigns Amid Trump Nod
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!